24/7 Market News Snapshot 14 August, 2025 – Abeona Therapeutics Inc. Common Stock (NASDAQ:ABEO)

August 14, 2025

DENVER, Colo., 14 August, 2025 (www.247marketnews.com) – (NASDAQ:ABEO) are discussed in this article.
Abeona Therapeutics Inc. is currently experiencing noteworthy momentum in the biopharmaceutical sector, with its stock opening at $6.85 and trading at $7.245, reflecting a notable increase of approximately 10.44%. This rise follows a previous session close of $6.56, showcasing a bullish outlook among investors. Current trading volume stands at 1.31 million shares, indicating heightened activity and keen interest in Abeona’s stock. The upward price movement may result from positive developments related to the company’s products or wider market trends, with significant resistance anticipated at the $7.50 threshold and support likely at $6.85. Close monitoring of volume changes will be essential for further assessments of price trajectories.

Abeona’s optimistic outlook is further bolstered by the recent FDA approval of its groundbreaking therapy, ZEVASKYN™ (prademagene zamikeracel), which represents a pioneering advancement as the first autologous cell-based gene therapy for the management of wounds in patients afflicted with recessive dystrophic epidermolysis bullosa (RDEB). The company is poised to launch ZEVASKYN in the third quarter of 2025, and has noted substantial interest from both healthcare providers and patients, supported by an established network of treatment centers.

Vish Seshadri, CEO of Abeona, emphasized the promising early traction surrounding ZEVASKYN, highlighting the strong commitment from the RDEB community and the company’s successful negotiations for payer coverage. Having received favorable insurance responses for all prior authorization requests submitted thus far, the therapy is positioned to make a significant impact in patient care.

Abeona’s robust financial footing is evidenced by its cash reserves of $226 million as of June 30, 2025, which are expected to sustain operations through the projected revenue from ZEVASKYN. Furthermore, the recent sale of a priority review voucher has generated $155 million, solidifying Abeona’s foundation while it continues to innovate and expand its portfolio to address unmet medical needs.

Related news for (ABEO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.